This page shows the publications co-authored by Bob Carter and Ralph Weissleder.
Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS One. 2018; 13(7):e0199414.
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015 May 11; 6:6999.
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. J Neurooncol. 2012 Oct; 110(1):37-48.
Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009 Sep; 94(3):373-82.
An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma. Nat Biomed Eng. 2021 07; 5(7):678-689.
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018 03; 4(3):eaar2766.
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012 Dec; 18(12):1835-40.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.